Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

An epithelial cell adhesion molecule- and CD3-bispecific antibody plus activated T-cells can eradicate chemoresistant cancer stem-like pancreatic carcinoma cells in vitro.

Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M, Morisaki T.

Anticancer Res. 2014 Aug;34(8):4509-19.

PMID:
25075094
2.

EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells.

Cioffi M, Dorado J, Baeuerle PA, Heeschen C.

Clin Cancer Res. 2012 Jan 15;18(2):465-74. doi: 10.1158/1078-0432.CCR-11-1270. Epub 2011 Nov 17.

3.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.

English DP, Bellone S, Schwab CL, Roque DM, Lopez S, Bortolomai I, Cocco E, Bonazzoli E, Chatterjee S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Cancer. 2015 Feb 1;121(3):403-12. doi: 10.1002/cncr.29062. Epub 2014 Sep 23.

4.

Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.

Dettmar K, Seitz-Merwald I, Lindemann C, Schroeder P, Seimetz D, Atz J.

Clin Transl Oncol. 2012 May;14(5):376-81. doi: 10.1007/s12094-012-0811-5.

PMID:
22551544
5.

Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1.

Bao B, Azmi AS, Aboukameel A, Ahmad A, Bolling-Fischer A, Sethi S, Ali S, Li Y, Kong D, Banerjee S, Back J, Sarkar FH.

J Biol Chem. 2014 May 23;289(21):14520-33. doi: 10.1074/jbc.M113.532887. Epub 2014 Apr 9.

6.

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.

Seimetz D, Lindhofer H, Bokemeyer C.

Cancer Treat Rev. 2010 Oct;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. Epub 2010 Mar 27. Review.

PMID:
20347527
8.

EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.

Mitra M, Kandalam M, Harilal A, Verma RS, Krishnan UM, Swaminathan S, Krishnakumar S.

Mol Vis. 2012;18:290-308. Epub 2012 Feb 1.

9.

Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody.

Wimberger P, Xiang W, Mayr D, Diebold J, Dreier T, Baeuerle PA, Kimmig R.

Int J Cancer. 2003 Jun 10;105(2):241-8.

10.
11.

New gene-immunotherapy combining TRAIL-lymphocytes and EpCAMxCD3 Bispecific antibody for tumor targeting.

Groth A, Salnikov AV, Ottinger S, Gladkich J, Liu L, Kallifatidis G, Salnikova O, Ryschich E, Giese N, Giese T, Momburg F, Büchler MW, Moldenhauer G, Herr I.

Clin Cancer Res. 2012 Feb 15;18(4):1028-38. doi: 10.1158/1078-0432.CCR-11-2767. Epub 2012 Jan 6.

12.

Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action.

Hirschhaeuser F, Walenta S, Mueller-Klieser W.

Cancer Immunol Immunother. 2010 Nov;59(11):1675-84. doi: 10.1007/s00262-010-0894-1. Epub 2010 Jul 21.

PMID:
20652245
13.

Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma.

Salnikov AV, Groth A, Apel A, Kallifatidis G, Beckermann BM, Khamidjanov A, Ryschich E, Büchler MW, Herr I, Moldenhauer G.

J Cell Mol Med. 2009 Sep;13(9B):4023-33. doi: 10.1111/j.1582-4934.2009.00723.x.

14.

An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression.

Zhang P, Shi B, Gao H, Jiang H, Kong J, Yan J, Pan X, Li K, Zhang P, Yao M, Yang S, Gu J, Wang H, Li Z.

Cancer Immunol Immunother. 2014 Feb;63(2):121-32. doi: 10.1007/s00262-013-1497-4. Epub 2013 Nov 1.

PMID:
24177984
15.

[T-cells activated with a trifunctional bi-specific antibody in head and neck cancer].

Gronau S, Schmitt M, Reinhardt P, Wiesneth M, Riechelmann H.

Laryngorhinootologie. 2005 Nov;84(11):822-8. German.

PMID:
16358189
16.

Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.

Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H, Riechelmann H, Wiesneth M, Gronau S.

Int J Oncol. 2004 Oct;25(4):841-8.

PMID:
15375531
17.

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.

Mau-Sørensen M, Dittrich C, Dienstmann R, Lassen U, Büchler W, Martinius H, Tabernero J.

Cancer Chemother Pharmacol. 2015 May;75(5):1065-73. doi: 10.1007/s00280-015-2728-5. Epub 2015 Mar 27.

PMID:
25814216
18.

Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cells.

Herrmann I, Baeuerle PA, Friedrich M, Murr A, Filusch S, Rüttinger D, Majdoub MW, Sharma S, Kufer P, Raum T, Münz M.

PLoS One. 2010 Oct 18;5(10):e13474. doi: 10.1371/journal.pone.0013474.

19.

Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-α.

Rossi EA, Rossi DL, Cardillo TM, Chang CH, Goldenberg DM.

Mol Cancer Ther. 2014 Oct;13(10):2341-51. doi: 10.1158/1535-7163.MCT-14-0345. Epub 2014 Jul 22.

20.

Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.

Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G, Krinner E, Bruckmeier S, Lippold S, Kischel R, Lutterbuese R, Kufer P, Baeuerle PA, Schlereth B.

Cancer Res. 2008 Jan 1;68(1):143-51. doi: 10.1158/0008-5472.CAN-07-2182.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk